InCROM Europe Plc

Tel: +44 (0)20 7395 6040
Fax: +44(0)20 7395 6044

Web: www.incrom.com

With the addition of our state of the art Early Phase research unit, ICRU, InCROM Europe is poised to offer a full service early clinical pharmacology development programme from Phase 0 to Phase IIa.

InCROM Europe is dedicated to providing the highest quality services to our Sponsors whilst ensuring the highest level of safety and comfort of our volunteers. ICRU is GCP and GMP certified and received MHRA Standard and Supplementary Accreditation in March 2009 giving us the ability to perform high risk studies that need to be reviewed by the Expert Advisory Group (EAG). Built within a private hospital in East London, InCROM Europe has access to a Level 3 ICU within the same building and all InCROM Europe medical staff are trained to ILS (nurses) and ALS (physicians) standards.

InCROM Europe is the ideal place to perform Sponsor’s entire Early Phase programmes. ICRU is accredited to perform FIH studies (both standard and high risk) which can be performed as a stand alone protocol or conducted with several arms under the one design (i.e. Food effect, Elderly, Gender, Race).

Being a world leader in performing Ethnic Bridging studies, InCROM Europe has recruited for over 45 protocols in Japanese, Korean and Chinese populations. Studies can be performed as a separate protocol or in combination with Caucasian SAD protocol.

InCROM Europe has also partnered with a renown NHS Trust and has performed several In Patient Patient PK studies for indications such as HCV and RA.

Group Sector

Geographical Area

• United Kingdom
• Japan
• China

Contact

Brendan Ellis, Business Development Manager

brendan.ellis@incrom.com